发布求助
文献互助 智能选刊 最新文献

Clinical Liver Disease最新文献

筛选
英文 中文
A review of drug-induced liver injury with rash, eosinophilia, and systemic symptoms (DRESS) syndrome: Cutaneous manifestations, clinical features, and management. 药物性肝损伤伴皮疹、嗜酸性粒细胞增多和全身症状（DRESS）综合征综述：皮肤表现、临床特征和处理方法。
Clinical Liver Disease Pub Date : 2024-05-31 eCollection Date: 2024-01-01 DOI: 10.1097/CLD.0000000000000198
Nitin Arora, Naga Chalasani, Sahand Rahnama-Moghadam
{"title":"A review of drug-induced liver injury with rash, eosinophilia, and systemic symptoms (DRESS) syndrome: Cutaneous manifestations, clinical features, and management.","authors":"Nitin Arora, Naga Chalasani, Sahand Rahnama-Moghadam","doi":"10.1097/CLD.0000000000000198","DOIUrl":"10.1097/CLD.0000000000000198","url":null,"abstract":"","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11146467/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141236185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic challenges in drug-induced liver injury. 药物性肝损伤的诊断难题。
Clinical Liver Disease Pub Date : 2024-05-31 eCollection Date: 2024-01-01 DOI: 10.1097/CLD.0000000000000206
Paul H Hayashi, Jay H Hoofnagle
{"title":"Diagnostic challenges in drug-induced liver injury.","authors":"Paul H Hayashi, Jay H Hoofnagle","doi":"10.1097/CLD.0000000000000206","DOIUrl":"10.1097/CLD.0000000000000206","url":null,"abstract":"","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11146506/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141236412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of opioid use disorder in patients with liver disease. 肝病患者阿片类药物使用障碍的治疗。
Clinical Liver Disease Pub Date : 2024-05-31 eCollection Date: 2024-01-01 DOI: 10.1097/CLD.0000000000000207
Jordana Laks, Daniel P Alford
{"title":"Treatment of opioid use disorder in patients with liver disease.","authors":"Jordana Laks, Daniel P Alford","doi":"10.1097/CLD.0000000000000207","DOIUrl":"10.1097/CLD.0000000000000207","url":null,"abstract":"","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11146471/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141236708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Metabolic dysfunction-associated steatotic liver disease and cardiovascular disease. 代谢功能障碍相关的脂肪肝和心血管疾病。
Clinical Liver Disease Pub Date : 2024-05-31 eCollection Date: 2024-01-01 DOI: 10.1097/CLD.0000000000000181
Tooba Laeeq, Kyaw Min Tun
{"title":"Metabolic dysfunction-associated steatotic liver disease and cardiovascular disease.","authors":"Tooba Laeeq, Kyaw Min Tun","doi":"10.1097/CLD.0000000000000181","DOIUrl":"10.1097/CLD.0000000000000181","url":null,"abstract":"","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11146514/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141236698","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Barriers to longitudinal follow-up for hepatitis B treatment in rural Sierra Leone: A mixed methods study of retention in care. 塞拉利昂农村地区乙肝治疗纵向随访的障碍：关于继续接受治疗的混合方法研究。
Clinical Liver Disease Pub Date : 2024-05-31 eCollection Date: 2024-01-01 DOI: 10.1097/CLD.0000000000000225
Williams Lebbie, Lao-Tzu Allan-Blitz, Emmanuel T Nyama, Mohamed Swaray, Daniel Lavalie, Michael Mhango, Marta Patiño Rodriguez, Neil Gupta, Remy Bitwayiki
{"title":"Barriers to longitudinal follow-up for hepatitis B treatment in rural Sierra Leone: A mixed methods study of retention in care.","authors":"Williams Lebbie, Lao-Tzu Allan-Blitz, Emmanuel T Nyama, Mohamed Swaray, Daniel Lavalie, Michael Mhango, Marta Patiño Rodriguez, Neil Gupta, Remy Bitwayiki","doi":"10.1097/CLD.0000000000000225","DOIUrl":"10.1097/CLD.0000000000000225","url":null,"abstract":"<p><p>HBV disproportionately affects resource-limited settings, and retaining patients in longitudinal care remains challenging. We conducted a mixed methods investigation to understand the causes of losses to follow-up within an HBV clinic in rural Sierra Leone. We developed a multivariable logistic regression model of baseline clinical and sociodemographic factors predicting losses to follow-up, defined as failing to present for a follow-up visit within 14 months of enrollment. We included patients enrolled between April 30, 2019 and March 1, 2020, permitting 14 months of follow-up by April 30, 2021. We then developed a survey to solicit patient perspectives on the challenges surrounding retention. We interviewed randomly selected patients absent from HBV care for at least 6 months. Among 271 patients enrolled in the Kono HBV clinic, 176 (64.9%) did not have a follow-up visit within 14 months of the study end point. Incomplete baseline workup (aOR 2.9; 95% CI: 1.6-4.8), lack of treatment at baseline (aOR 5.0; 95% CI: 1.7-14.4), and having cirrhosis at baseline (aOR 3.3; 95% CI: 0.99-10.8) were independently associated with being lost to follow-up. For the patient survey, 21 patients completed the interview (median age 34 years [IQR: 25-38]). Travel-related factors were the most frequently reported barrier to retention (57%). Almost 30% suggested improved customer care might support retention in care; 24% requested to be given medication. In our setting, factors that might reduce losses to follow-up included expanded criteria for treatment initiation, overcoming transportation barriers, reducing wait times, ensuring against stockouts, and scaling up point-of-care testing services.</p>","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11146505/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141236297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Understanding fatigue and pruritus in primary biliary cholangitis. 了解原发性胆汁性胆管炎的疲劳和瘙痒。
Clinical Liver Disease Pub Date : 2024-05-31 eCollection Date: 2024-01-01 DOI: 10.1097/CLD.0000000000000216
Asma Faisal
{"title":"Understanding fatigue and pruritus in primary biliary cholangitis.","authors":"Asma Faisal","doi":"10.1097/CLD.0000000000000216","DOIUrl":"10.1097/CLD.0000000000000216","url":null,"abstract":"","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11146472/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141236743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patients treated with immune checkpoint inhibitors for HCC should be considered for liver transplantation. 接受免疫检查点抑制剂治疗的 HCC 患者应考虑接受肝移植。
Clinical Liver Disease Pub Date : 2024-05-08 eCollection Date: 2024-01-01 DOI: 10.1097/CLD.0000000000000107
Media N Ismael, Calvin Kiani, Virginia Clark
{"title":"Patients treated with immune checkpoint inhibitors for HCC should be considered for liver transplantation.","authors":"Media N Ismael, Calvin Kiani, Virginia Clark","doi":"10.1097/CLD.0000000000000107","DOIUrl":"10.1097/CLD.0000000000000107","url":null,"abstract":"<p><p></p>","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11078524/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140891580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of HBV reactivation: Challenges and opportunities. HBV 再激活的管理：挑战与机遇。
Clinical Liver Disease Pub Date : 2024-05-08 eCollection Date: 2024-01-01 DOI: 10.1097/CLD.0000000000000143
Catherine Mezzacappa, Joseph K Lim
{"title":"Management of HBV reactivation: Challenges and opportunities.","authors":"Catherine Mezzacappa, Joseph K Lim","doi":"10.1097/CLD.0000000000000143","DOIUrl":"10.1097/CLD.0000000000000143","url":null,"abstract":"<p><p></p>","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11078521/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140891578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reasonable expansion of surgical candidates for HCC treatment. 合理扩大 HCC 治疗手术候选者的范围。
Clinical Liver Disease Pub Date : 2024-05-08 eCollection Date: 2024-01-01 DOI: 10.1097/CLD.0000000000000153
Samuel D Butensky, Kevin G Billingsley, Sajid A Khan
{"title":"Reasonable expansion of surgical candidates for HCC treatment.","authors":"Samuel D Butensky, Kevin G Billingsley, Sajid A Khan","doi":"10.1097/CLD.0000000000000153","DOIUrl":"10.1097/CLD.0000000000000153","url":null,"abstract":"<p><p></p>","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11078523/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140891584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patients treated with immune checkpoint inhibitors for HCC should not be considered for liver transplant. 接受免疫检查点抑制剂治疗的 HCC 患者不应考虑进行肝移植。
Clinical Liver Disease Pub Date : 2024-05-08 eCollection Date: 2024-01-01 DOI: 10.1097/CLD.0000000000000108
Frances Lee, Ann Robinson, Edward Will Holt, R Todd Frederick
{"title":"Patients treated with immune checkpoint inhibitors for HCC should not be considered for liver transplant.","authors":"Frances Lee, Ann Robinson, Edward Will Holt, R Todd Frederick","doi":"10.1097/CLD.0000000000000108","DOIUrl":"10.1097/CLD.0000000000000108","url":null,"abstract":"<p><p></p>","PeriodicalId":10377,"journal":{"name":"Clinical Liver Disease","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11078522/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140891581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信